Lower urinary tract symptoms and prostate cancer: is PSA testing in men with symptoms wise?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 25 citations in OpenAlex.

1. The Benefits and Harms of Screening for Prostate Cancer in Adults Aged 18 Years and Older: A Systematic Review.Current oncology (Toronto, Ont.) · 2026
   Pooled it
2. Epidemiology of prostate cancer in Nigeria: a mixed methods systematic review.Cancer causes & control : CCC · 2025
   Pooled it
3. Ethnic differences in prostate-specific antigen levels in men without prostate cancer: a systematic review.Prostate cancer and prostatic diseases · 2023
   Pooled it
4. Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients.BMC medicine · 2022
   Pooled it
5. Utility of prostate-specific antigen density and its correlation with Gleason grade groups: a hospital-based cross-sectional study among patients with prostate-related urinary symptoms at Bugando Medical Centre, Mwanza, Tanzania.BMC urology · 2026
   Article
6. Prostate specific antigen retesting intervals and trends in England: population based cohort study.BMJ (Clinical research ed.) · 2025
   Article
7. Early economic evaluation of magnetic resonance imaging for prostate cancer detection in primary care.BJUI compass · 2024
   Article
8. Multifaceted role of erlotinib in various cancer: nanotechnology intervention, patent landscape, and advancements in clinical trials.Medical oncology (Northwood, London, England) · 2024
   Review
9. Association between physical activity levels and lower urinary tract symptoms: a cohort study in 20,732 Brazilian men.Einstein (Sao Paulo, Brazil) · 2024
   Article
10. Prostate malignant tumor and benign prostatic hyperplasia microenvironments in black African men: Limited infiltration of CD8+ T lymphocytes, NK-cells, and high frequency of CD73+ stromal cells.Cancer reports (Hoboken, N.J.) · 2023
    Article
11. Screening for prostate cancer: protocol for updating multiple systematic reviews to inform a Canadian Task Force on Preventive Health Care guideline update.Systematic reviews · 2022
    Article
12. Urinary symptoms and prostate cancer-the misconception that may be preventing earlier presentation and better survival outcomes.BMC medicine · 2022
    Article
13. E-cadherin deficiency promotes prostate macrophage inflammation and bladder overactivity in aged male mice.Aging · 2022
    Article
14. Do the Prostate-Specific Antigen (PSA) Tests That Are Ordered in Clinical Practice Adhere to the Pertinent Guidelines?Journal of clinical medicine · 2021
    Article
15. The elusive diagnosis of cancer: testing times.The British journal of general practice : the journal of the Royal College of General Practitioners · 2018
    Article

Corrections and comments

• Commented on by
  The elusive diagnosis of cancer: testing times.2018
• Comment on
  Screening for prostate cancer.2013

Authors and funding

3 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as